Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Trastuzumab deruxtecan monotherapy and combinations in patients with advanced/metastatic HER2-positive (HER2+) G/GEJ adenocarcinoma

Breaking Science in Gastrointestinal Cancer Video Series

Login to get immediate access to this content.

Login

Speaker: Yelena Y. Janjigian, USA

Abstract discussed:

  • 1401O - Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03): Watch the presentation from ESMO 2024 now

The speakers and studies featured in this video series were selected independently by ESMO.

Published October 2024

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.